Page 436 - IJB-10-6

International Journal of Bioprinting 3D-bioprinted respiratory disease model

3. Macias A, McElhaney J, Chaves S, et al. The disease burden of 17. Vastani Z, Ahmadi A, Abounoori M, et al. Interleukin‐29 profiles in
influenza beyond respiratory illness. Vaccine. 2021;39:A6-A14. COVID‐19 patients: survival is associated with IL‐29 levels. Health
doi: 10.1016/j.vaccine.2020.09.048 Sci Rep. 2022;5(2):e544.
doi: 10.1002/hsr2.544
4. World Health Organization. Influenza (Seasonal).
https://www.who.int/news-room/fact-sheets/detail/influenza- 18. Niu J, Wu S, Chen M, et al. Hyperactivation of the NLRP3
(seasonal). Accessed January 24, 2024 inflammasome protects mice against influenza A virus infection via
IL-1β mediated neutrophil recruitment. Cytokine. 2019;120:115-124.
5. Yamauchi Y. Chapter one – influenza A virus uncoating. Adv Virus doi: 10.1016/j.cyto.2019.04.019
Res. 2020;106:1-38.
doi: 10.1016/bs.aivir.2020.01.001 19. Robinson K, Choi S, McHugh K, et al. Influenza A exacerbates
staphylococcus aureus pneumonia by attenuating IL-1β production
6. Suarez D. Influenza A virus. In: Animal Influenza. Ames, Iowa, in mice. J Immunol. 2013;191(10):5153-5159.
USA:John Wiley & Sons, Inc.;2017:1-29. doi: 10.4049/jimmunol.1301237
doi: 10.1002/9781118924341.ch1
20. Wang W, Yang P, Zhong Y, et al. Monoclonal antibody against
7. Julkunen I, Melen K, Nyqvist M, Pirhonen J, Sareneva T, Matikainen CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced
S. Inflammatory responses in influenza A virus infection. Vaccine. acute lung injury. Cell Res. 2013;23:577-580.
2000;19(1):S32-S37. doi: 10.1038/cr.2013.25
doi: 10.1016/S0264-410X(00)00275-9
21. Hayney M, Henrique K, Barnet J, et al. Serum IFN-γ-induced
8. Borau M, Stertz S. Entry of influenza A virus into host cells protein 10 (IP-10) as a biomarker for severity of acute respiratory
– recent progress and remaining challenges. Curr Opin Virol. infection in healthy adults. J Clin Virol. 2017;90:32-37.
2021;48:23-29. doi: 10.1016/j.jcv.2017.03.003
doi: 10.1016/j.coviro.2021.03.001
22. Zimmerling A, Zhou Y, Chen X. Bioprinted constructs for
9. Zhang Y, Xu Z, Cao Y. Host-virus interaction: how host cells defend respiratory tissue engineering. Bioprinting. 2024;24:1-29.
against influenza A virus infection. Viruses. 2020;12(4):376. doi: 10.1016/j.bprint.2024.100135
doi: 10.3390/v12040376
23. O’Leary C, Gilbert J, O’Dea S, O’Brien F, Cryan S. Respiratory tissue
10. Mifsud E, Kuba M, Barr I. Innate immune responses to engineering: current status and opportunities for the future. Tissue
influenza virus infections in the upper respiratory tract. Viruses. Eng Part B Rev. 2015;21(4):323-344.
2021;13(10):2090. doi: 10.1089/ten.TEB.2014.0525
doi: 10.3390/v13102090
24. Shrestha J, Paudel K, Nazari H, et al. Advanced models for respiratory
11. Gu Y, Zuo X, Zhang S, et al. The mechanism behind influenza virus disease and drug studies. Med Res Rev. 2023;43(5):1470-1504.
cytokine storm. Viruses. 2021;13(7):1362. doi: 10.1002/med.21956
doi: 10.3390/v13071362 25. Baroon S, Saez J, Owens R. In vitro models for studying respiratory
12. Julkunen I, Sareneva T, Pirhonen J, Ronni T, Melen K, Matikainen host–pathogen interactions. Adv Biol. 2021;5(6).
S. Molecular pathogenesis of influenza A virus infection and virus- doi: 10.1002/adbi.202000624
induced regulation of cytokine gene expression. Cytokine Growth 26. Bouvier N, Lowen A. Animal models for influenza virus
Factor Rev. 2001;12(2-3):171-180. pathogenesis and transmission. Viruses. 2010;2(8):1530-1563.
doi: 10.1016/S1359-6101(00)00026-5 doi: 10.3390/v20801530
13. Betakova T, Kostrabova A, Lachova V, Turianova L. Cytokines 27. Nguyen T, Rollon R, Choi Y. Animal models for influenza research:
induced during influenza virus infection. Curr Pharm Des. strengths and weaknesses. Viruses. 2021;13(6):1011.
2017;23(18):2616-2622. doi: 10.3390/v13061011
doi: 10.2174/1381612823666170316123736
28. Chen X, Anvari-Yazdi A, Duan X, et al. Biomaterials/bioinks and
14. Matsushima K, Yang D, Oppenheim J. Interleukin-8: an evolving extrusion bioprinting. Bioact Mater. 2023;28:511-536.
chemokine. Cytokine. 2022;153:155828. doi: 10.1016/j.bioactmat.2023.06.006
doi: 10.1016/j.cyto.2022.155828
29. Mahfouzi S, Tali S, Amoabediny G. 3D bioprinting for lung and
15. Can F, Ozkurt Z, Ozturk N, Sezen S. Effect of IL-6, IL-8/CXCL8, IP- tracheal tissue engineering: criteria, advances, challenges, and
10/CXCL 10 levels on the severity in COVID 19 infection. Int J Clin future directions. Bioprinting. 2021;21:e00124.
Pract. 2021;75(12):e14970. doi: 10.1016/j.bprint.2020.e00124
doi: 10.1111/ijcp.14970
30. Carpio M, Dabaghi M, Ungureanu J, Kolb M, Hirota J, Moran-
16. Wang J, Oberley-Deegan R, Wang S, et al. Differentiation human Mirabal J. 3D bioprinting strategies, challenges, and opportunities
alveolar type II cells secrete antiviral IL-29 (IFN-λ1) in response to to model the lung tissue microenvironment and its function. Front
influenza A infection. J Immunol. 2012;188(5):1924-1932. Bioeng Biotechnol. 2021;9:773511.
doi: 10.4049/jimmunol.1101987 doi: 10.3389/fbioe.2021.773511

Volume 10 Issue 6 (2024) 428 doi: 10.36922/ijb.3895